DCS Versus DES for One-month DAPT in Patients With ACS: ONE-PASS Trial (ONE-PASS)
Drug-Coated Stent Versus Drug-Eluting Stent for One-month Dual-antiplatelet Therapy in Patients With Acute Coronary Syndrome: ONE-PASS Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Sung-Jin Hong, MD, PhD
- Phone Number: +82-2-2228-8452
- Email: hongs@yuhs.ac
Study Contact Backup
- Name: Chul-Min Ahn
- Phone Number: +82-2-2228-8532
- Email: drcello@yuhs.ac
Study Locations
-
-
-
Seoul, Korea, Republic of
- Recruiting
- Yonsei Cardiovascular Hospital, Yonsei University College of Medicine
-
Contact:
- Chul-Min Ahn
- Phone Number: 82-2-2228-8532
- Email: drcello@yuhs.ac
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥19 years
- All subjects who are acceptable candidates for treatment with a drug-coated stent or drug-eluting stent because of acute coronary syndrome
- Provision of informed consent
Exclusion Criteria:
- Current or potential pregnancy
- Need of oral anticoagulation therapy
- Inability to follow the patient over the period of 1 year after enrollment, as assessed by the investigator
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: DCS group
Drug-coated stent group
|
The polymer-free drug-coated stent (BioFreedom Ultra stent) will be implanted for the DCS group.
Other Names:
|
|
Active Comparator: DES group
Drug-eluting stent group
|
The Biodegradable polymer drug-eluting stent (Ultimaster stent) will be implanted for the DES group.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patient-Oriented Composite Endpoint (POCE)
Time Frame: At 1 year after randomization
|
The composite of all-cause death, MI, or any revascularization
|
At 1 year after randomization
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Device-Oriented Composite Endpoint (DOCE)
Time Frame: At 1 year after randomization
|
The composite of cardiovascular death, MI (not clearly attributable to a non-target vessel), or clinically-driven target-lesion revascularization (TLR)
|
At 1 year after randomization
|
|
All-cause death
Time Frame: At 1 year after randomization
|
All death including cardiovascular death
|
At 1 year after randomization
|
|
Cardiovascular death
Time Frame: At 1 year after randomization
|
Death resulting from cardiovascular causes or undetermined cause of death not attributable to any other category because of the absence of any relevant source documents
|
At 1 year after randomization
|
|
Myocardial infarction
Time Frame: At 1 year after randomization
|
A spontaneous event according to the fourth universal definition of myocardial infarction and the Academic Research Consortium-2 Consensus Document
|
At 1 year after randomization
|
|
Stroke
Time Frame: At 1 year after randomization
|
Loss of neurologic function caused by an ischemic or hemorrhagic event
|
At 1 year after randomization
|
|
Stent thrombosis (definite or probable)
Time Frame: At 1 year after randomization
|
By the Academic Research Consortium-2 Consensus Document
|
At 1 year after randomization
|
|
Any revascularization
Time Frame: At 1 year after randomization
|
All revascularizations including target-vessel revascularization and and non-target-vessel revascularization
|
At 1 year after randomization
|
|
Target-vessel revascularization
Time Frame: At 1 year after randomization
|
Clinically indicated or ischemia driven any repeat percutaneous intervention or surgical bypass of any segment of the target vessel including the target lesion
|
At 1 year after randomization
|
|
Non-target vessel revascularization
Time Frame: At 1 year after randomization
|
Clinically indicated or ischemia driven any repeat percutaneous intervention or surgical bypass of any segment of the non-target vessel
|
At 1 year after randomization
|
|
Target-lesion revascularization
Time Frame: At 1 year after randomization
|
Clinically indicated or ischemia driven repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion
|
At 1 year after randomization
|
|
BARC type 2-5 bleeding
Time Frame: At 1 year after randomization
|
According to a consensus report from the Bleeding Academic Research Consortium
|
At 1 year after randomization
|
|
BARC type 3-5 bleeding
Time Frame: At 1 year after randomization
|
According to a consensus report from the Bleeding Academic Research Consortium
|
At 1 year after randomization
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Chul-Min Ahn, Yonsei University Health System, Severance Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 1-2021-0089
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.